top of page
Empowering patients fighting substance addiction
From addiction biology to empowering patients
Astraea Therapeutics is a clinical-stage company developing life-changing medicines for patients fighting to overcome substance addiction to opioid painkillers, smoking, and habitual psychostimulants. Astraea’s platform technology centers around the neurobiology of relapse.
Astraea is developing oral medicines that focus on two key pathways in the brain, one genetically linked to addictive behaviors and the other shown by clinical imaging to be altered in patients struggling with addiction.
Astraea making strides
Novel drug candidate with a first-in-class mechanism for smoking cessation & abstinence, advancing into clinical development
Dr. Nurulain T. Zaveri, PhD
President and Chief Scientific Officer
Science Translational Medicine
Cover Story: No Pain, all gain
"AT-121, a small molecule agonist of two opioid receptors, mediates analgesia without opioid-associated side effects in nonhuman primates"
Astraea in the Spotlight
320 Logue Avenue
Mountain View, CA 94043
bottom of page